CS Capital

Lingmo Medical is a company that provides department-level flexible endoscopic solutions.It is advancing the development of flexible endoscopy and providing higher-quality endoscopic solutions for clinicians and patients, allowing more risk categories to benefit from it. Benefit from endoscopic diagnosis and treatment.

Hengyu Biotechnology is a specialized provider of biological testing services aimed at drug developers. Founded by a scientific research team, the company focuses on delivering comprehensive biosafety testing solutions for innovative pharmaceutical companies worldwide. Its services include viral clearance process validation, cell bank validation, replicative virus testing, batch release testing, CGT bioanalysis, and process residue testing. These offerings are designed to meet regulatory filing requirements across the United States, China, and Europe, supporting the entire life cycle of biologics from research and development to marketing.

Biointron, founded in 2012 and based in Shanghai, China, specializes in the development of recombinant antibody technology and offers contracted research organization (CRO) services. The company focuses on accelerating the antibody discovery process by providing a comprehensive range of services, including rapid expression platforms, antibody sequencing, and labeling tools. Through its innovative technology, Biointron achieves high-throughput recombinant antibody production, supplying customers with high-quality and cost-effective recombinant protein and antibody reagents.

Baiying Bio offers economic recombinant protein and antibody reagents and is a CRO vendor for life science researchers and biopharma companies. They provide services including HTP recombinant antibody and VHH production, bispecific antibody production, antibody humanization, VHH library generation, hybridoma sequencing, protein expression in mammalian cells, large-scale antibody production, and more. They delivered tens of thousands of recombinant antibodies to customers.

Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To meet the therapeutic product needs of our clients at the pre-clinical, clinical, and commercial stages, we offer end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

Hengyu Biotechnology is a specialized provider of biological testing services aimed at drug developers. Founded by a scientific research team, the company focuses on delivering comprehensive biosafety testing solutions for innovative pharmaceutical companies worldwide. Its services include viral clearance process validation, cell bank validation, replicative virus testing, batch release testing, CGT bioanalysis, and process residue testing. These offerings are designed to meet regulatory filing requirements across the United States, China, and Europe, supporting the entire life cycle of biologics from research and development to marketing.

Future Vision is a visual health service organization based in Shanghai, specializing in the prevention and control of myopia, amblyopia rehabilitation training, and medical optometry for children aged 3 to 16. The company utilizes advanced North American optometry technology to deliver its services, aiming to address the growing concerns of visual health among children. By focusing on early intervention and comprehensive eye care, Future Vision seeks to improve the visual outcomes for its young clientele.

Laekna Therapeutics is a clinical-stage biotechnology company focused on drug discovery and development, primarily targeting significant unmet medical needs in oncology and liver diseases. The company has built a robust research and development infrastructure to facilitate the transition of therapeutic molecules from discovery through to registrational trials. Laekna is currently conducting six clinical trials, including three multi-regional trials aimed at addressing treatment-resistant cancers. Its two Core Products, LAE002, an ATP-competitive AKT inhibitor for ovarian cancer, and LAE001, are central to its therapeutic strategy, supported by an additional 14 pipeline candidates. By prioritizing innovative solutions, Laekna Therapeutics aims to enhance treatment options for patients facing challenging medical conditions.

InxMed is a clinical-stage biotechnology company dedicated to developing innovative cancer therapeutics aimed at improving treatment outcomes for patients. The company focuses on creating "Best-in-Disease Combination" medicines, which are designed to target various forms of cancer, including pancreatic, ovarian, and gastric cancers. InxMed's approach is grounded in a thorough understanding of disease biology and pharmacology, allowing for the development of novel treatment options. The company is committed to establishing a robust translational platform that combines advanced expertise with efficient execution capabilities to enhance the effectiveness of cancer therapies available to healthcare professionals and their patients.

G7 is a company that specializes in fleet management systems aimed at optimizing the transportation ecosystem. With a significant installation base of 800,000 cargo vehicles across China, G7 utilizes proprietary hardware devices to gather and analyze data for logistics companies and drivers. The company's platform enables businesses to locate and monitor transportation vehicles, track driver behaviors, and estimate departure and arrival times. Additionally, G7 provides detailed insights on route optimization, fuel consumption, and cargo conditions, such as temperature and humidity, which helps corporate clients and business owners enhance the efficiency of their transportation networks.

Tavotek Biotherapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic medicines for patients with severe diseases that lack effective treatments. The company is led by experienced pharmaceutical executives who have successfully developed numerous biologics currently on the market. Tavotek employs three distinct research and development platforms: TavoSelect, an innovative Phage Display Library; TavoPrecise, an engineering platform for tissue-specific biologics; and TavoMIP, a multicyclic peptide platform. This diverse array of technologies supports Tavotek's extensive pipeline of product candidates, which targets cancers, autoimmune disorders, and infectious diseases, thereby addressing significant unmet medical needs in the healthcare landscape.

Biointron, founded in 2012 and based in Shanghai, China, specializes in the development of recombinant antibody technology and offers contracted research organization (CRO) services. The company focuses on accelerating the antibody discovery process by providing a comprehensive range of services, including rapid expression platforms, antibody sequencing, and labeling tools. Through its innovative technology, Biointron achieves high-throughput recombinant antibody production, supplying customers with high-quality and cost-effective recombinant protein and antibody reagents.

Eighteeth focuses on the research and production of dental instruments. Eighteeth has 14 product categories including endo motor, apex locator, ultrasonic scaler, curing light, X-Ray unit, intraoral sensor, intraoral scanner, and owns 110 authorized patents.

Ab&B Biotech focuses on the research and development of innovative human vaccines and multivalent vaccines.

Cipher Gene is a biomedical data analysis and interpretation platform that focuses on integrating bioinformatics, molecular and medical genetics, and statistics. The company collaborates with clinical laboratories to ensure accurate and efficient interpretation of various biological data, including genomics and transcriptomics. By leveraging artificial intelligence technology, Cipher Gene provides genetic diagnostic and analysis services, particularly in the field of childhood genetic diseases, enabling physicians to make informed treatment decisions. Additionally, Cipher Gene is committed to developing its own biomedical database and AI-based data analysis platform, enhancing precision medicine and facilitating scientific research and personalized studies.

Beijing Tuo Rui Detection Technology Co., Ltd., founded in 2013 and based in China, specializes in the research, development, and production of diagnostic and testing products for animal health. The company focuses on medical equipment for pets and other animals, offering a range of testing solutions that include biochemical, routine, genetic, immunological, and microbiological testing. By providing advanced diagnostic tools, Beijing Tuo Rui Detection Technology aims to enhance medical diagnosis and therapy for animals, ensuring better health management and care for pets.